**Lactobacillus paracasei** CBA L74 Metabolic Products and Fermented Milk for Infant Formula Have Anti-Inflammatory Activity on Dendritic Cells *In Vitro* and Protective Effects against Colitis and an Enteric Pathogen *In Vivo*

Elena Zagato¹, Erika Mileti¹, Lucia Massimiliano¹, Francesca Fasano², Andrea Budelli², Giuseppe Penna¹*, Maria Rescigno¹*

¹Department of Experimental Oncology, European Institute of Oncology, Milan, Italy, ²R&D, Heinz Italia S.p.A., Latina, Italy

**Abstract**

The rapid expansion of commercially available fermented food products raises important safety issues particularly when infant food is concerned. In many cases, the activity of the microorganisms used for fermentation as well as what will be the immunological outcome of fermented food intake is not known. In this manuscript we used complex *in vitro*, *ex-vivo* and *in vivo* systems to study the immunomodulatory properties of probiotic-fermented products (culture supernatant and fermented milk without live bacteria to be used in infant formula). We found *in vitro* and *ex-vivo* that fermented products of *Lactobacillus paracasei* CBA L74 act via the inhibition of proinflammatory cytokine release leaving anti-inflammatory cytokines either unaffected or even increased in response to *Salmonella* typhimurium. These activities are not dependent on the inactivated bacteria but to metabolic products released during the fermentation process. We also show that our *in vitro* systems are predictive of an *in vivo* efficacy by the fermented products. Indeed CBA L74 fermented products (both culture medium and fermented milk) could protect against colitis and against an enteric pathogen infection (*Salmonella* typhimurium). Hence we found that fermented products can act via the inhibition of immune cell inflammation and can protect the host from pathobionts and enteric pathogens. These results open new perspectives in infant nutrition and suggest that *L. paracasei* CBA L74 fermented formula can provide immune benefits to formula-fed infants, without carrying live bacteria that may be potentially dangerous to an immature infant immune system.

**Citation:** Zagato E, Mileti E, Massimiliano L, Fasano F, Budelli A, et al. (2014) Lactobacillus paracasei CBA L74 Metabolic Products and Fermented Milk for Infant Formula Have Anti-Inflammatory Activity on Dendritic Cells *In Vitro* and Protective Effects against Colitis and an Enteric Pathogen *In Vivo*. PLoS ONE 9(2): e87615. doi:10.1371/journal.pone.0087615

**Editor:** Fabio Cominelli, CWRU/UH Digestive Health Institute, United States of America

**Received** November 5, 2013; **Accepted** December 21, 2013; **Published** February 10, 2014

**Copyright:** © 2014 Zagato et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** The work was supported by Heinz. The funders supplied the fermented milk. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** Francesca Fasano and Andrea Budelli are employees of Heinz. The rest of the authors have declared that they have no conflict of interest.

This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: giuseppe.penna@ieo.eu (GP); maria.rescigno@ieo.eu (MR)

**Introduction**

In the initial years of human life the microbiota is established and several environmental factors contribute to its generation, including nutrition [1,2]. The microbiota then plays a major role in the development of the immune system [3,4]. Thus the interplay between nutrition, microbiota and immune cells is decisive for the subsequent health of the infant [5].

Exclusive breast-feeding is recommended from birth to 6 months of age [6,7]. Breast milk is involved in the development of a bifidobacteria-enriched microbiota [8], in protection against potentially infectious agents [9] and the correct development of secondary lymphoid organs and the immune system [10]. Infant formulae are intended to serve as a substitute for breast milk in infants who cannot be fed at breast, should not receive breast milk, or for whom breast milk is not available [11].

It is known that infant formula does not recapitulate many of the effects of breast-feeding as it does not impact on thymus size [10] or microbiota composition [8].

Although human milk represents the gold standard, at present no infant formula is able to reproduce the whole composition and daily variability of human milk. Recent developments in infant formulae have therefore been targeted towards reproducing the functional effects, rather than the qualitative composition, of human milk [12].

Even though more evidence on clinical trials is required, fermented infant formula (FIF) without live bacteria has been shown to be beneficial for several aspects of the well-being of infants [13]. It has been shown that FIF administration in infants can increase the amount of bifidobacteria in the feces and fosters the development of poliovirus-specific IgAs in response to Pentacoq vaccination, as compared to infants treated with standard non-fermented formula (SF) [14]. Another study...
compared three groups of term neonates: 30 newborns were breast-fed and 60 were randomized to receive either FIF or SF. Infants were followed up for 4 months. They showed that breast-fed and FIF treated infants had comparable thymus indexes and lower fecal pH than SF-treated infants, suggesting that FIF may have similar effect to maternal milk [15]. Another study tested the effect of long-term administration on 971 infants (4–6 months of age) of FIF or SF with a similar nutritional composition on incidence or severity of acute diarrhea [16]. They found that there was no difference in the number or duration of diarrhea episodes, but there was a reduction in the severity of the episodes in the FIF group, including fewer medical consultations and fewer changes to other formulas [16]. Similarly, a randomized clinical trial compared long-term treatment with FIF or SF of newborns with high risk of allergy until the age of 1 year old. While there was no difference in the proportion of infants affected by cow’s milk allergy, infants administered FIF had reduced positive skin prick tests to cow’s milk. FIF seems to be beneficial also in pre-term infants. While there was no major difference in the anthropometric data, pre-term infants treated with FIF displayed reduced abdominal distension from the second week of treatment [17]. Differently from term infants, there was no bifidogenic property of the FIF and secreted IgAs were increased in FIF treated infants, but only if the infants had been partially breast-fed, suggesting that FIF can boost the maternal IgA response [17].

Hence, FIF has been shown to be safe, to have similar nutritional properties of standard formula, and to mimic some effects of maternal milk, in vivo. However, several bacteria can be used to ferment milk, including probiotics, bacteria considered to be beneficial to the host. However, the choice of probiotics to be used should not be arbitrary as each strain may produce specific metabolites in the fermented product with distinctive immunomodulatory properties [18]. For instance, when we compared the activity of several Lactobacillus and their metabolic products - that we called postbiotic [19] - on the immune system, we found that each strain has very peculiar characteristics [19,20,21]. We found that Lactobacillus plantarum v299 has detrimental effects due to its immunostimulatory properties in mice and on healthy human intestinal tissue [20,21], while LGG and L. paracasei B21090 can be detrimental on inflamed tissues like those coming from patients with inflammatory bowel disease [20]. By contrast, the activity of postbiotics is very safe also on inflamed tissues presumably because postbiotics lack the microbe associated molecular patterns that may further activate inflamed tissues [20].

In this manuscript, in the attempt to define the immunomodulatory properties of fermented milk powder preparations for infant formula without living bacteria, we analyzed the activity of metabolic products released by Lactobacillus paracasei CBA L74 during fermentation of culture media or milk for infant formula. We studied their properties in vitro, on one of the most important immune target (the dendritic cells, DCs) that are the initiators of immunity or tolerance; ex-vivo, using an organ culture model set up in our laboratory and in vivo in mice, during inflammation (colitis) or infection (Salmonella infection).

Materials and Methods

Mice and bacterial strains

C57/BL6 mice were purchased from Charles River laboratories. All mice were maintained in microisolator cages in a specific pathogen-free animal facility. All experiments were performed in accordance with the guidelines established in the Principles of Laboratory Animal Care (directive 86/609/EEC) and approved by the Italian Ministry of Health.

Lactobacillus paracasei CBA L74 (Heinz Italia SpA, Latina, Italy), International Depository Accession Number LMG P-24778 was grown in MRS broth (Bio lag diagnosti s) in semi-anaerobic conditions. Salmonella enterica serovar typhimurium strain SL1344 (FB62) was provided by G. Dougan (The Wellcome Trust Sanger Institute, UK) and grown in LB broth.

CFU numbers were controlled by plating.

Lactobacillus paracasei CBA L74 and Salmonella FB62 supernatants were obtained growing bacteria to OD600 = 0.6 in MRS and LB respectively and filtering the resulting medium.

Cells and reagents

DCs were derived from human peripheral blood monocytes selected with anti-CD14 antibodies coupled to magnetic beads (Miltenyi, Bologna, Italy). CD14+ cells were incubated for 6 days in complete medium containing granulocyte-macrophage colony stimulating factor (GM-CSF, 5 ng/mL; BD Biosciences) and interleukin-4 (2.5 ng/mL; BD Biosciences) in order to obtain immature MoDCs.

MoDCs were incubated with either Salmonella FB62 (MOI 10:1 bacteria:DC) or Lactobacillus paracasei CBA L74 (MOI 10:1) for 1 hour in the presence of 2% LB, MRS, CBA L74 supernatant (in MRS) or FB62 supernatant. After extensive wash cells were incubated for 24 hours in the presence of gentamicin (100 µg/mL). Supernatants were tested for cytokine abundance and cells were analyzed by FACS for activation and maturation markers: HLA-DR FITC (BD) and CD83 APC (BD) respectively.

Milk powders

Milk products in powder were provided by HJ Heinz (Heinz Italia SpA, Latina, Italy).

The fermented milk was prepared from skim milk fermented by Lactobacillus paracasei CBA L74 (Heinz Italia SpA, Latina, Italy), International Depository Accession Number LMG P-24778. The fermentation is started in the presence of 109 bacteria, reaching 1010 colony-forming units/ml after a 15-hour incubation at 37°C. After heating at 85°C for 20 seconds, in view of inactivating the live bacteria, the formula is spray-dried. The final fermented milk powder (FM) contains bacterial bodies and fermentation products.

The control (non-fermented milk, NFM) consists of skimmed milk powder with the same basal nutrient composition of fermented milk powder (grams per 100 g): proteins, 35; lipids, 1; carbohydrates, 54.

Milk powders were resuspended at 1.41 g/100 ml in boiling water.

Preparation of the control and fermented milk diets

The diets (control and fermented milk) had similar nutrient composition and were prepared as pellets at Mucedola, Settimo Milanese, Italy. The diets were a mixture of 95% standard rat/mice chow ref. 4RF21 (Mucedola, Settimo Milanese, Italy) and 5% of the fermented milk or non-fermented milk, respectively.

Ex-vivo organ culture

The protocol developed in the lab by Tsilingiri K. et al. [20] for human intestinal explant culture was modified for murine colon tissue. Briefly: 25 mm² chunks of murine colon were fixed to the cylinder. Tissue was incubated with non-fermented and fermented milk inside the cylinder for 1 hour at 37°C 5% CO2 and then infected with 107 CFU FB62 resuspended in 50 µl of the respective preparation. After 2 hours at 37°C 5% CO2 infection medium was removed and gentamicin (100 µg/ml) added in the
culture medium. Tissues were incubated for 24 hours in oxygen chamber, then culture media were analysed for cytokine production and tissues fixed for paraffin embedding and histological evaluation.

DSS colitis

Mice were administered intragastrically for 14 consecutive days (from day -2 to day 11) with 200 μl of vehicle, MRS, live CBA L74, supernatant of CBA L74, non-fermented milk or fermented milk. When special diets were used mice were fed with modified diet from day 2 until the end of the experiment.

Acute colitis was induced supplementing drinking water with DSS 3% (w/v) for 8-9 days. Recovery in plain water was allowed until the end of the experiment.

Body weight and survival were assessed daily.

Salmonella survival

After receiving modified diet for 10 days mice were intragastrically infected with 10^6 CFU FB62 in 200 μl carbonate buffer. Survival was assessed daily.

Histological analysis

4 μm sections from colon swiss rolls were stained with Hematoxylin-Eosin (HE) standard protocol. Histological eva-
tion of the grade of colitis was performed according to the following histological grading system: 0 normal colonic mucosa; 1 minimal to mild inflammation restricted to the mucosa; 2 moderate inflammation in the mucosa, only occasionally extending to the submucosa; 3 moderate to severe inflammation involving the mucosa with shortening or loss of the crypts, extending into the submucosa and occasionally into the tunica muscularis; 4 severe transmural inflammation in the mucosa, submucosa, tunica muscularis, and subserosa, usually associated with mucosal ulceration. Additionally, the number of lymphoid aggregates was counted and the grade of colon edema (0 = absent; 1 = minimal; 2 = mild; 3 = moderate; 4 = severe) was evaluated. For each colon also the total number of ulcers and the number of healing ulcers (i.e. re-epithelialized ulcers) were counted. According to their size, ulcers were classified as follows: small = <10 crypts (or <1 field at 400x); medium = 10–20 crypts (<1 field at 100x) in width; large = >20 crypts (>1 field at 100x) in width. Arbitrarily, a value of 1 was assigned to each small ulcer, a value of 2 to each medium ulcer, and a value of 4 to each large ulcer. The total ulcer score was then calculated for each colon as follows: Total ulcer score = no. of small ulcers × 1 + no. of medium ulcers × 2 + no. of large ulcers × 4.

Cytokine measurements

IL-10, IL-6, KC and TNF-α concentrations were determined by Cytokine bead array (Becton Dickinson) and IL-12p70 concentration was determined by commercially available ELISA (R&D systems). Optical densities were measured on a Bio-Rad DynaTech Laboratories ELISA reader at a wavelength of 450 nm (Hercules, CA, USA). CBA-associated Cytol fluorimetry was measured by FACs array (Becton Dickinson).

Anti-inflammatory index was calculated as ratio between IL-10 and IL-12% of response relative to FB62 stimulation.

RT-qPCR assay

Colon were homogenised in 500 ul of TRIsol (Invitrogen). RNA was extracted adding 100 ul of chloroform, precipitating the RNA with RNeasy Mini Kit (QIAGEN). RNA was retro-transcribed with ImProm-II Reverse Transcriptase kit (Promega) following manufacturer’s instruction. qPCR assay was performed with Fast Sybr Green Master Mix (Life Technologies) on 10 ng cDNA template/reaction using exon-spanning primers. QuantiTect Primer Assays were used for Il22, Reg3γ and Reg3β. Other primers are listed in Table S1. The Spearman’s rank correlation coefficient among cytokine expression levels and inflammatory parameters was determined using GraphPad Prism.

Results

Metabolic products from CBA L74 have a high anti-inflammatory index

Probiotics or their metabolic products can induce a particular type of cytokine profile depending on their inflammatory or anti-inflammatory properties [21,22,23]. However, when probiotics or their metabolic products have anti-inflammatory properties, their activity is best appreciated when they are tested concomitantly with a strong inflammatory agent [21]. To test the activity of *Lactobacillus paracasei* CBA L74, we incubated human monocyte derived dendritic cells (MoDCs) with either the live bacteria, or its supernatant of culture after centrifugation and ultrafiltration in the presence or absence of *Salmonella typhimurium* (FB62), which induces a strong inflammatory response in DCs [21]. As shown in Fig. 1A, while *Salmonella* induced a high production of the inflammatory cytokine IL-12p70 and of the anti-inflammatory cytokine IL-10, CBA L74 alone induced very little IL-12p70. Culture supernatant of FB62 alone, but not of CBA L74, induced some cytokine production by the MoDCs with higher IL-10 than IL-12p70 (Fig. S1). However when tested together with *Salmonella*, only the supernatant from CBA L74 had the ability to drastically reduce IL-12p70 and increase IL-10 (Fig. 1A-B). The net result was a strong anti-inflammatory index associated only to supernatant of CBA L74 when coincubated with *Salmonella* (Fig. 1C). By contrast, the same anti-inflammatory activity was not observed coincubating the DCs with *Salmonella* in the presence of the whole CBA L74 bacteria (Fig. S1B). The anti-inflammatory effect of CBA L74 sn was not due to inhibition of DC maturation (Fig. S1C).

Consistent with our previous results on a different *Lactobacillus* strain (B21090) [21], the activity was so strong that it was evident at a concentration of 2% of supernatant of bacterial culture, which is equivalent to the number of bacteria used to stimulate the DCs. This suggests that in the short period of stimulation before antibiotic killing, the bacteria are not able to release the metabolic products in a sufficient amount to observe the anti-inflammatory effect. Hence, metabolic products released by CBA L74 have strong anti-inflammatory activity on DCs stimulated with *Salmonella*.

Metabolic products of CBA L74 protect against colitis in vivo

Probiotics have been proposed for the treatment or prevention of inflammatory bowel disease, however only in pouchitis and ulcerative colitis some beneficial effects were observed [18,24]. We have shown that probiotics can be detrimental if administered to inflamed tissues ex-vivo probably because of boosting an ongoing inflammation, while postbiotics may be a safer alternative as they can inhibit current inflammatory responses [20]. Hence, we wanted to assess whether we could administer probiotics or postbiotics to mice in order to prevent colitis development. Mice were pretreated with either CBA L74 orally, or its culture supernatant or unfermented culture medium intraperitoneally for two days, and then received DSS into the drinking water to induce colitis while on treatment. We decided to use the intraperitoneal administration of the supernatant to avoid possible degradation of the metabolic products due to transit in the stomach acidic environment. Mice were followed for signs of colitis development (body weight and presence of blood in feces). At the end of the experiment mice were sacrificed and intestinal tissues were collected for histological analysis. As shown in Fig. 2A, adminis-
Figure 3. Fermented milk preparation has anti-inflammatory properties on MoDCs. MoDCs were infected with *Salmonella* FB62 (MOI 10:1) for 1 hour in medium without antibiotics or in different infant formulas: non-fermented milk (NFM) and fermented milk (FM) obtained through fermentation of *Lactobacillus* CBA L74 alone (CBA L74), fermentation in the presence of *S. thermophilus* TH3 (S. th) or double fermentation with CBA L74 and *S. thermophilus* TH3 (CBA L74 + S. th). After washing and 24 h incubations in medium with antibiotics cytokine abundance was evaluated. Panels show % of response of IL-12p70 and IL-10 relative to MoDCs infected with SL1334 in medium without antibiotics. *** p < 0.001.
doi:10.1371/journal.pone.0087615.g003
oration of live bacteria to mice prior to DSS administration was highly detrimental, as mice lost weight similarly to untreated animals, but they all died in a few days. By contrast, intraperitoneal injection of CBA L74 fermented culture supernatant resulted in protection against colitis by reducing weight loss and favoring recovery of the mice (Fig. 2B). Also the unfermented culture medium had some protective effect, but the effect of the fermented medium was higher both as reduced weight loss, colitis grade, lymphoid aggregates and number and size of ulcers (Fig. 2C). Colitis score was assessed as described in material and methods section. The histological analysis indicated that the tissue of mice treated with CBA L74 fermented culture supernatant

![Figure 4. Oral administration of fermented milk preparation protects against colitis.](https://example.com/figure4.png)

A. Single mouse body weight curves, Kaplan-Meier survival and colon length for vehicle, NFM and FM. B. Body weight curves (mean ± SEM) for two pooled experiments. * p<0.05; ** p<0.01. doi:10.1371/journal.pone.0087615.g004
displayed a healthy morphology (Fig. 2D), whether this is due to a better recovery or to protection against the inflammatory effects of the DSS-induced colitis is difficult to ascertain at this time point. However, the finding that mice lost weight similarly to the MRS unfermented control medium but recovered faster would indicate that an effect on the recovery phase may have occurred.

Hence, we found that CBA L74 fermented medium has anti-inflammatory activity in vitro on DCs and has protective effect in vivo against colitis.

**Fermented milk powder preparations for infant formula have anti-inflammatory properties in vitro**

Having shown that CBA L74 fermentation leads to the generation of anti-inflammatory metabolic products that protect against colitis in vivo, we wanted to assess whether fermented food that may be administered to healthy infants also retains similar anti-inflammatory activity and whether this may result in protection against colitis or infectious diseases. We first tested whether reconstituted fermented milk powder preparations for infant formula (FM) had similar anti-inflammatory activity on the major immune cell targets that are the dendritic cells. To our knowledge this is the first attempt to assess which cell types may be the target of FM. MoDCs were incubated with reconstituted FM or non-fermented milk powder for infant formula (NFM) and/or a strong inflammatory infectious agent (Salmonella typhimurium) for 1 h and then thoroughly washed to eliminate any remaining milk and to reduce the bacterial burden. Cells were then incubated in a medium containing gentamycin to kill all the remaining Salmonella. We used two different fermented preparations, one containing only CBA L74 and another one with CBA L74 and S. thermophilus. While both formulations of FM alone had no major cytokine-inducing property (not shown), when coincubated with S. typhimurium, they both reduced IL-12p70 production while preserving the production of IL-10 by the dendritic cells (Fig. 3). The anti-inflammatory index was very high and significantly different from the one of the non-fermented milk (that was not different from Salmonella alone) for both FM formulations (Fig. 3). The two FM formulations did not statistically differ, even though the one obtained with CBA L74 and S. thermophilus had greater anti-inflammatory activity. The anti-inflammatory activity of the FM was not due to the dead bacteria present in the preparation as NFM added with heat killed bacteria had no anti-inflammatory properties (not shown).

**Fermented milk for infant formula has protective effect against colitis in vivo when administered orally**

As shown earlier, DCs can be the target of the anti-inflammatory activity of FM in vitro, similarly to what observed with fermented culture medium. We then wondered whether also FM had colitis protective effects in vivo. Mice received FM (fermented with CBA L74 and S. thermophilus) or NFM by oral gavage for 14 consecutive days (from day 0). Starting from day 0 they also received DSS in their drinking water for 9 days. Mice were analyzed for development of colitis as reported above. As shown in Fig. 4A–B, mice receiving FM lost less weight and recovered faster than mice receiving vehicle or NFM. The mice all survived DSS but the colon length was much higher for mice receiving FM. Similar results were obtained with a preparation of FM obtained only with CBA L74 fermentation (in the absence of the starter S. thermophilus) indicating that the protective effects were due to the metabolic activity of CBA L74 (Fig. 5A). In addition, while the colitis score was very similar between the two groups, mice receiving FM had much reduced numbers and size of ulcers and lymphoid aggregates (Fig. 5B) and showed a better recovery of the morphology of the tissue, as shown by histological analysis (Fig. 5C).

We then analyzed whether we could observe differences in cytokine expression in the intestines of mice pretreated with FM or NFM that may explain the protective effect of FM. We found no statistically significant differences in the two groups, but there was a tendency to a reduction in Th1 polarization (as attested by reduced expression of Tbet and IFN-γ in intestinal cells) (Fig. 6). There was also a slight reduction in IL-17a and Gata-3 expressing cells. Interestingly, we observed a tendency towards an increase in IL-33 and Cyclooxygenase (Cox)-2 production in the FM group, indicating that there is a concomitant reduction of pathologic cytokines (IFN-γ and IL-17a) and increase of protective factors (IL-33 and Cox-2). However, when we analyzed the cytokine expression in relation to the inflammatory parameters, we found that some cytokines/transcription factors that were differentially expressed between the two groups but that did not reach statistical significance, were associated to the number of ulcers in a statistically significant way. In particular, IL-33 was inversely correlated to the number of ulcers (r Spearman = −0.638, p = 0.048) while T-bet, Gata-3 and IFN-γ were directly correlated with the number of ulcers (r Spearman 0.792, p = 0.011).

As, for experimental difficulties, the amount of FM that was administered by gavage did not resemble the amount of FM an infant would introduce with the formula, we decided to prepare a special diet containing 5% of fermented milk. Mice were fed the FM or NFM-containing diet for 14 days as before and were treated with DSS starting from day 9 for 5 consecutive days. As shown in Fig. S2, also increasing the amount of fermented milk ingested via the diet we observed a drastic protection of mice from DSS colitis. While 90% of the mice died when exposed to NFM containing diet, only 30% of the mice died when fed with FM-diet and they all recovered (Fig. S2).

**FM for infant formula protects against a lethal dose of Salmonella typhimurium infection**

An important characteristic a FM should have, when thinking to infant nutrition, is protection against enteric pathogens. One of the major pathogens of the mouse gastrointestinal tract is Salmonella typhimurium [25]. We wanted to test whether FM would protect against S. typhimurium infection. We adopted two strategies: an \textit{ex-vivo} one, to strictly control the infection and to assess the direct effect of the FM on intestinal tissue in response to Salmonella and an \textit{in vivo} one, using a mouse model of infection. In the experiments \textit{ex-vivo}, we used an organ culture model system established in our laboratory that we can use to stimulate in a polarized fashion [20]. In fact we glue a cave cylinder on the apical face of the intestinal villi that allows to confine the size of the infection and to avoid spreading of bacteria on the broken edges of the tissue, thus preserving tissue polarity and permitting physiological stimulation
Probiotic Fermented Milk is Anti-Inflammatory

The figure illustrates the levels of various cytokines and genes in non-fermented milk (NFM) and fermented milk (FM). The plots show the concentration of cytokines Tbet, Gata3, Ifn-γ, IL-17a, IL-6, IL-22, IL-33, IL-1b, Kc, Ccl2, Cox2, iNos, Ahr, Indo, Zo-1, Reg3b, and Reg3g in NFM and FM. The data is presented in arbitrary units (AU) and indicates a lower expression of pro-inflammatory markers in the fermented milk compared to non-fermented milk, suggesting anti-inflammatory properties.
The cylinder is then excised and the tissue can be analyzed for histology and the supernatant for cytokine production. We found that FM could drastically reduce the amount of the inflammatory cytokines KC (the equivalent of human IL-8), IL-6 and TNF-α, produced in response to Salmonella and to limit tissue destruction (See Fig. 7A-B). In the experiments in vivo, we fed the mice with a FM-containing diet for ten days and then challenged the mice with a lethal dose of S. typhimurium. As shown in Fig. 7C, mice receiving FM-diet died with a statistically significantly slower kinetic than mice receiving NFM-diet, indicating a slight protection against a lethal dose of Salmonella.

**Discussion**

In 2007 a concerted action between the world health organization (WHO) and the UNICEF defined a ‘Global Strategy for Infant and Young Child Feeding’ to raise awareness on the importance of a proper nutrition for infants till the age of 5 (http://www.who.int/nutrition/topics/global_strategy/en/). In this document it is highlighted the importance of facilitating mothers to exclusively breastfeeding in the first 6 months of life.

If, for whatever reason, human milk becomes unavailable to an infant, then during the first 6 months of life a new-generation cows’ milk formula that is closer to the gold standard of human milk should be used. Infant formulae are the only alternatives to breast milk for infants who are unable to continue breastfeeding through the first year of life [12].

In order to mimic some benefits observed in breast-fed infants, functional ingredients such as fermented milk have been added to infant formulae in recent years.

Even though there are several reports on the use of fermented formula in infants, only a few studies have been carried out so far to understand which are the immune cell targets of fermented milk preparations (without live bacteria) for infant formula and what are their major effects in vivo in animals in order to understand their mechanisms of action. It has been shown that heat-treated fermented formula (Bifidobacterium breve C50 and Streptococcus thermophilus 065) does not interfere with the establishment of oral tolerance but it strengthens the epithelial barrier properties [26].

Here, we compared the immunological properties of fermented and non fermented milk for formula preparations. We found that bacterial culture medium or milk fermented with L. paracasei CBA L74 has strong anti-inflammatory properties on dendritic cells in response to the inflammatory enteric pathogen Salmonella typhimurium. This indicates that during fermentation, L. paracasei CBA L74 produces metabolites that play an important role in controlling the dendritic cell response to inflammatory agents. The DCs were capable of fully mature (both phenotypically and morphologically) but were producing less IL-12p70 in response to Salmonella, while IL-10 release was not affected. Overall, both CBA L74-fermented culture medium and milk displayed a potent anti-inflammatory index (the ratio between IL-10 and IL-12p70 production). We also tested if the dead bacteria (thus mimicking the effect of killing bacteria by heat after fermentation) may be responsible of the anti-inflammatory activity of the milk, but dead L. paracasei was not influencing the inflammatory activity of Salmonella. This has led us to test the effect of these metabolic products also in vivo in mice after colitis induction or infection.

Interestingly, we found that CBA L74- fermented culture medium could contrast the onset of colitis (there was a statistically significant reduction in weight loss) and favor the recovery of mice thus completely protecting them from colitis-induced death. Of note, while the administration of fermented milk was protective, the administration of live bacteria was detrimental, leading to mice death. This has important implications when considering the use of fermented formulas containing live probiotics, as these may be dangerous when administered to a non-immune infant host.

When we tested the properties of fermented milk, we found that it displayed protective effects against colitis when administered intragastrically and this correlated with a reduced expression, which was however not statistically significant, of the pathologic Th1 cytokine IFN-γ in the colons of treated mice. We also observed a tendency to IL-33 increased production in mice fed with FM. IL-33, a member of the IL-1 family, signals via the ST-2 receptor and is responsible for the polarization of Th2 T cells [27]. It is upregulated in patients with inflammatory bowel disease [28], however whether it has pathological or protective effects is still a matter of debate. Indeed, in some models of colitis the absence of the IL-33/ST-2 axis is protective, suggesting a pathologic role of IL-33 [29,30]; while in others the absence of IL-33 results in reduced recovery and mouse death, indicating a protective role [31,32]. Interestingly, the protective effect of IL-33 seems to be exerted in the recovery phase [32], presumably via the activation of Fopx3+ regulatory T cells [31]. Because we found an increase in IL-33 during the recovery phase in the FM-treated group, it is likely that this cytokine has a protective function in this phase, however as this difference was not statistically significant we cannot consider it as directly related to the overall anti-inflammatory effect exerted by the fermented milk. We also observed an increased but not statistically significant expression of Cox-2 in the FM-treated group. Global deletion or chemical inhibition of Cox-2 results in exacerbated colitis [33,34], suggesting a protective role for Cox-2 during intestinal injury. Hence, small differences towards reduction of pro-inflammatory IFN-γ producing cells and increase of protective cytokines (IL-33) or enzymes (Cox-2) may be responsible for the overall protective effect of FM against colitis and may not reach statistical significance when considered individually. The colitis-protective effect was observed also when the fermented milk powder was added to the pellet diet. By contrast the non-fermented milk did not display any protective effect suggesting that the fermentation in itself is responsible for the observed effect.

Another important characteristic of breast milk is that it can protect against enteric pathogens. This characteristic is often associated to the IgAs that are passively delivered to the pups via the milk [35,36]. However, it is also possible that milk-associated microbiota [37] or its metabolic products may reinforce the epithelial barrier or the immune system against pathogens. By comparing mice fed with fermented or non-fermented milk preparations, we could address this issue as there are no mother-derived IgAs, and analyze if fermented milk could protect against enteric infections. We found that mice fed with the fermented milk preparation displayed a slightly longer survival to a lethal dose of Salmonella. This indicates that L. paracasei CBA L74 metabolic products released in the milk have enteric pathogen protective effects. Indeed, the exposure of colon explants to a fermented milk
Probiotic Fermented Milk is Anti-Inflammatory

A

KC fold change (relative to NI)

IL-6 fold change (relative to NI)

TNF-a fold change (relative to NI)

NFM  FM  NFM  FM  NFM  FM

B

NFM

FM

C

percent survival

days

NFM  FM

0  10  20  30

0  20  40  60  80  100

*  **
preparation resulted in a reduced capacity of the pathogen to cause inflammation and tissue destruction. Whether the latter effect is a consequence of the reduced inflammation or the reduced capacity of Salmonella to infect the tissue remains to be established. We also do not know whether the fermented products are strengthening the barrier properties of the epithelium besides reducing the inflammation.

The capacity of postbiotics to protect against colitis or pathogen infection has been reported also for other bacterial strains. Lactobacillus brevis SBC8803 derived polyphosphate is capable of protecting mice against DSS-induced colitis, acting on the p38 MAPK pathway and suppressing intestinal permeability induced by oxidants [38]. The p40 molecule, produced and secreted by Lactobacillus GG, is the main mediator for ameliorating DSS and oxazolone-induced inflammation, through its binding to EGFR. Activation of EGFR by p40 was sufficient to reduce cytokine-oxazolone-induced inflammation, through its binding to EGFR. We also do not know whether the fermented products are strengthening the barrier properties of the epithelium besides reducing the inflammation.

In conclusion, we have shown that L. paracasei CBA L74 fermented milk preparations for infant formula have a strong anti-inflammatory activity in vitro and protect against colitis or enteric pathogens in vivo. This opens new perspectives in infant nutrition and suggests that L. paracasei CBA L74 fermented formula can provide some immune benefits to formula-fed infants, without carrying potentially dangerous live bacteria.

### Supporting Information

**Figure S1** A. MoDCs were incubated for 1 h with CBA L74 supernatant (Sn CBA L74), FB62 supernatant (Sn FB62), MRS or LB. After washing and 24 h incubations, concentrations of IL-12p70 and IL-10 were determined by ELISA and CBA assays. Concentrations are shown as % of response relative to untreated MoDCs. B. MoDCs were infected with either Salmonella FB62 (MOI 10:1) or Lactobacillus CBA L74 (MOI 10:1) for 1 hour in medium without antibiotics or in the presence of CBA L74 supernatant (Sn CBA L74). After washing and 24 h incubations in medium with antibiotics, cytokine abundance was evaluated. C. MoDCs were infected for 1 h with either Salmonella FB62 (MOI 10:1) or Lactobacillus CBA L74 (MOI 10:1) for 1 hour in medium without antibiotics, washed, incubated for 24 h and analysed at FACS for CD83 and HLA-DR surface markers. * p < 0.05; *** p < 0.001.

**Table S1** List of forward and reverse primers used for Q-PCR of the reported genes.

**Author Contributions**

Conceived and designed the experiments: GP MR. Performed the experiments: EZ EM LM. Analyzed the data: GP MR. Contributed reagents/materials/analysis tools: FF AB. Wrote the paper: MR GP.

### References

1. Palmer C, Bik EM, Duggan DB, Relman DA, Brown PO (2007) Development of the human infant intestinal microbiota. PLoS Biology 5: e177.
2. Marjan JC, Farzan SF, Hibiherd PI, Karagas MR (2012) Normal neonatal microbe home variation in relation to environmental factors, infection and allergy. Current opinion in pediatrics 24: 753–759.
3. Maynard CL, Eilen CO, Hatton RD, Weaver CT (2012) Reciprocal interactions of the intestinal microbeota and immune system. Nature 489: 231–241.
4. Hooper LV, Littman DR, Macpherson AJ (2012) Interactions between the microbeota and the immune system. Science 336: 1268–1273.
5. Sim K, Powell E, Shaw AG, McClure Z, Bangham M, et al. (2013) The neonatal gastrointestinal microbiota: the foundation of future health? Archives of disease in childhood Fetal and neonatal edition 98: F602–304.
6. Cattaneo A, Bumaz B, Areilhu M, Nihon I, Mikael-Kostyra K, et al. (2010) Protection, promotion and support of breast-feeding in Europe: progress from 2002 to 2007. Public health nutrition 13: 751–759.
7. Agostini C, Braegger C, Desai T, Kodack S, Koletzko B, et al. (2009) Breast-feeding: A commentary by the ESPGHAN Committee on Nutrition. Journal of pediatric gastroenterology and nutrition 49: 112–125.
8. Harmen HJ, Wildeboer-Velos AG, Raasen GC, Wagendorp AA, Klijn N, et al. (2000) Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. Journal of pediatric gastroenterology and nutrition 30: 61–67.
9. Howie PW, Forsyth JS, Ogston SA, Clark A, Florcy CD (1990) Protective effect of breast feeding against infection. BMJ 300: 11–16.
10. Hasselbalch H, Jørgensen DB, Engelund MD, Michaelsen KF, Nielsen MB (1996) Decreased thyminus size in formula-fed infants compared with breastfed infants. Acta paediatrica 85: 1029–1032.
11. Koletzko B, Baker S, Cleghorn G, Neto UF, Gopalan S, et al. (2005) Global standard for the composition of infant formula: recommendations of an ESPGHAN coordinated international expert group. Journal of pediatric gastroenterology and nutrition 41: 584–599.
Probiotic Fermented Milk is Anti-Inflammatory

12. Riva E, Verdúc E, Agostoni C, Giovannini M (2005) Closer to the gold standard: an appraisal of formulae available in Italy for use in formula-fed infants. The Journal of international medical research 33: 595–611.

13. Agostoni C, Goulet O, Kolacek S, Koletzko B, Moreno L, et al. (2007) Fermented infant formulae without live bacteria. Journal of pediatric gastroenterology and nutrition 44: 392–397.

14. Muller C, Yazourh A, Thibault H, Oudou MF, Singer E, et al. (2004) Increased polo virus-specific intestinal antibody response coincides with promotion of Bifidobacterium longum-infants and Bifidobacterium breve in infants: a randomized, double-blind, placebo-controlled trial. Pediatric research 56: 791–795.

15. Indriro F, Landia G, Mautone A, Montagna O (2007) Effect of a fermented formula on thymus size and stool pH in healthy term infants. Pediatric research 62: 98–100.

16. Thibault H, Aubert-Jacquin C, Goulet O (2004) Effects of long-term consumption of a fermented infant formula (with Bifidobacterium breve c50 and Streptococcus thermophilus 065) on acute diarrhoea in healthy infants. Journal of pediatric gastroenterology and nutrition 39: 147–152.

17. Campoots F, Suau A, Kapel N, Magne F, Viallon V, et al. (2011) A fermented formula in pre-term infants: clinical tolerance, gut microbiota, down-regulation of faecal calprotectin and up-regulation of faecal secretory IgA. The British journal of nutrition: 1–10.

18. Klaenhammer TR, Kleerebezem M, Kopp MV, Rescigno M (2012) The impact of probiotics and prebiotics on the immune system. Nature reviews Immunology 12: 728–734.

19. Tsilingiri K, Barbossa T, Penna G, Caprilli F, Sonzogni A, et al. (2012) Probiotic and postbiotic activity in health and disease: comparison on a novel polarised ex-vivo organ culture model. Gut.

20. Mileti E, Matteoli G, Biev ID, Rescigno M (2009) Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy. PLoS One 4: e7036.

21. Grangerette C, Nuten S, Palumbo E, Mortad S, Hermann C, et al. (2005) Enhanced anti-inflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. PNAS: In Press.

22. Foligne B, Nutten S, Grangette C, Dennin V, Goudercourt D, et al. (2007) Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J Gastroenterol 13: 236–243.

23. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, et al. (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479–490.

24. Pastorelli L, De Salvo C, Vecchi M, Pizzorno TT (2013) The role of IL-33 in gut mucosal inflammation. Mediators of inflammation 2013: 608147.

25. Pushparaj PN, Li D, Komai-Koma M, Guabiraba R, Alexander J, et al. (2013) Interleukin-33 exacerbates acute colitis via interleukin-4 in mice. Immunology 140: 70–77.

26. Menard S, Candahl C, Ben Ahmed M, Rakotobe S, Gaboriau-Routhiau V, et al. (2006) Stimulation of immunity without alteration of oral tolerance in mice fed with heat-treated fermented infant formula. Journal of pediatric gastroenterology and nutrition 43: 451–458.

27. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, et al. (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479–490.

28. Pushparaj PN, Li D, Komai-Koma M, Guabiraba R, Alexander J, et al. (2013) Interleukin-33 exacerbates acute colitis via interleukin-4 in mice. Immunology 140: 70–77.

29. Nethon MA, Pichery M, Murdoch JR, Foligne B, Ortega N, et al. (2012) Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut.

30. Duan L, Chen J, Zhang H, Yang H, Zhu P, et al. (2012) Interleukin-33 ameliorates experimental colitis through promoting T(H)2/FoxP3 regulatory T-cell responses in mice. Molecular medicine 18: 753–761.

31. Oboki K, Ohno T, Kajiwara N, Arai K, Morita H, et al. (2010) IL-33 is a crucial amplifier of innate rather than acquired immunity. Proceedings of the National Academy of Sciences of the United States of America 107: 18510–18515.

32. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, et al. (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479–490.

33. Pastorelli L, De Salvo C, Vecchi M, Pizzorno TT (2013) The role of IL-33 in gut mucosal inflammation. Mediators of inflammation 2013: 608147.

34. Reuter BK, Asaha S, Burret A, Sharkey KA, Wallace JL (1996) Excacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. The Journal of clinical investigation 98: 2076–2083.

35. Ward TL, Hosié S, Ishikawa I, Altschau I (2013) Human milk metagenome: a functional capacity analysis. BMC microbiology 13: 116.

36. Pushparaj PN, Li D, Komai-Koma M, Guabiraba R, Alexander J, et al. (2013) Interleukin-33 exacerbates acute colitis via interleukin-4 in mice. Immunology 140: 70–77.

37. Ward TL, Hosié S, Ishikawa I, Altschau I (2013) Human milk metagenome: a functional capacity analysis. BMC microbiology 13: 116.

38. Segawa S, Fujya M, Konishi H, Ueno N, Kobayashi N, et al. (2011) Probiotic-derived polyphosphate enhances the epithelial barrier function and maintains intestinal homeostasis through integrin-p38 MAPK pathway. PLoS One 6: e23278.

39. Pastorelli L, De Salvo C, Vecchi M, Pizzorno TT (2013) The role of IL-33 in gut mucosal inflammation. Mediators of inflammation 2013: 608147.

40. Kato-Mori Y, Orihashi T, Kanai Y, Sato M, Sera K, et al. (2010) Fermentation exerts bacteriocidal effects in mice. Journal of medicinal food 13: 1460–1467.